EP 4243829 A1 20230920 - METHODS OF ADMINISTERING RELUGOLIX
Title (en)
METHODS OF ADMINISTERING RELUGOLIX
Title (de)
VERFAHREN ZUR VERABREICHUNG VON RELUGOLIX
Title (fr)
MÉTHODES D'ADMINISTRATION DU RÉLUGOLIX
Publication
Application
Priority
- US 202063112523 P 20201111
- US 202163151423 P 20210219
- EP 2021081304 W 20211110
Abstract (en)
[origin: WO2022101303A1] This disclosure relates to combined oral preparations of N-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea (Compound 1), and a P-gp inhibitor or a combination of a P-gp inhibitor and a CYP3A inhibitor, and methods of treatment and uses for prostate cancer, uterine fibroids, endometriosis, adenomyosis, heavy menstrual bleeding, or pain associated with uterine fibroids, endometriosis, and adenomyosis comprising their administration.
IPC 8 full level
A61K 31/519 (2006.01); A61K 31/40 (2006.01); A61K 31/4196 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/565 (2006.01); A61K 31/57 (2006.01); A61K 31/7048 (2006.01); A61K 45/06 (2006.01); A61P 5/30 (2006.01); A61P 5/34 (2006.01); A61P 15/00 (2006.01); A61P 15/12 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP)
A61K 31/40 (2013.01); A61K 31/4196 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/565 (2013.01); A61K 31/57 (2013.01); A61K 31/7048 (2013.01); A61K 45/06 (2013.01); A61P 5/30 (2017.12); A61P 5/34 (2017.12); A61P 15/00 (2017.12); A61P 15/12 (2017.12); A61P 35/00 (2017.12)
Citation (search report)
See references of WO 2022101303A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022101303 A1 20220519; EP 4243829 A1 20230920; JP 2023549196 A 20231122
DOCDB simple family (application)
EP 2021081304 W 20211110; EP 21810968 A 20211110; JP 2023528189 A 20211110